Eli Lilly and Company

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Abcellera Biologies Inc.

Abcellera Biologics Inc.

Qing Chai

Jonathan Wesley Day

Robert William Siegel

Robert John Konrad

Oliver Schroeder

Yuewei Qian

Barney S Graham

Julian Davies

John Mascola

Bryan Edward Jones

Christopher Carl Frye

Wei Shi

Lingshu Wang

Kizzmekia S Corbett

Julie Ledgerwood

Jeffrey Streetman Boyles

John Michael Sauder

Kevin Jepson

Wing-pui Kong

Anna Pustilnik

Yi Zhang

Stefanie Zentelis

Ester Falconer

Denisa Foster

Olubukola Abiona

Ganapathy Gopalrathnam

Kathryn Westendorf

Krithika Muthuraman

Jörg Hendle

Yiqing Feng

Stephanie Marie Truhlar

Pia Pauliina Yachi

Petra Verdino

Kristin Paige Newburn

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

Anti-ANGPTL 3/8 complex antibodies and methods of using the same

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anti-coronavirus antibodies and methods of use

Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.

Polynucleotides for preparing ANGPTL 3/8 complexes

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anti-ANGPTL &#x215c; complex antibodies and methods of using the same

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

ANGPTL3/8 complexes and methods of using the same

The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.

PD-1 agonist antibodies and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Qing Chai